Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18123Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.date.accessioned | 2015-11-24T18:50:40Z | - |
| dc.date.available | 2015-11-24T18:50:40Z | - |
| dc.identifier.issn | 1879-1484 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18123 | - |
| dc.rights | Default Licence | - |
| dc.subject | Clinical Trials as Topic | en |
| dc.subject | Drug Toxicity | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/*pharmacology | en |
| dc.subject | Kidney/pathology | en |
| dc.subject | Liver/drug effects/injuries/*metabolism | en |
| dc.subject | Muscles/drug effects/*metabolism | en |
| dc.subject | Neoplasms/pathology | en |
| dc.subject | Randomized Controlled Trials as Topic | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Statin-associated adverse effects beyond muscle and liver toxicity | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.atherosclerosis.2006.10.001 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17094994 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0021915006006034/1-s2.0-S0021915006006034-main.pdf?_tid=2d386705f8d72dc2b59c208f49951b4a&acdnat=1333532550_c6bf82dbeeec9aaf119cc7ab7e9a3c35 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Randomized controlled trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have consistently demonstrated significant reductions in cardiovascular morbidity and mortality. Statins are currently the most widely used drugs in many countries. The most important adverse effects are associated with muscle and liver toxicity. However, with increased use and dose of statins and their over-the-counter availability in some countries more cases of other rare side effects may be seen in clinical practice. In the present article we review the literature concerning the statin-related adverse effects other than muscle and liver injury and we provide insight into their clinical relevance and possible underlying mechanisms. | en |
| heal.journalName | Atherosclerosis | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kiortsis-2007-Statin-associated ad.pdf | 161.81 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
